A phase 1/2 trial of HEC169096 in advanced solid tumours, run by Sunshine Lake Pharma Co., Ltd., now recruiting.
HEC169096 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05451602 by Sunshine Lake Pharma Co., Ltd., with 456 participants planned, started 2022-10-21 and due to reach its primary completion in 2026-12-30. Interventions recorded: HEC169096.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.